Financial News

Waldencast Acquires Novaestiq & US Rights to Injectable Hyaluronic Acid Gel Line

Saypha products will join the Obagi medical brand.

Waldencast acquired Novaestiq Corp. (Novaestiq), an aesthetic and medical dermatological innovations company. It includes the US rights to the Saypha line of hyaluronic acid (HA) injectable gels.

The strategic acquisition expands Obagi Medical’s offerings beyond US medical-grade skincare.

“We are excited to further diversify Obagi Medical’s portfolio of medical-grade skincare with consumer-centric, in-office injectable procedures through the introduction of the Obagi Medical Saypha ChIQ and MagIQ lines of injectable HA gels,” said Michel Brousset, co-founder and CEO of Waldencast. “Adding proven products into our portfolio increases our addressable market and allows us to deliver solutions for professionals and patients seeking both skincare and aesthetic treatments, all under the trusted Obagi Medical brand.”

Keep Up With Our Content. Subscribe To Happi Newsletters